Education
About Us
Working with TipRanks
Follow Us
Amneal Pharmaceuticals Inc (AMRX)
NASDAQ:AMRX
Earnings Data
Report Date
May 01, 2026Before Open (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
0.18Last Year’s EPS
0.21Same Quarter Last Year
Strong Buy
Based on 4 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call communicated solid financial progress (8% revenue growth, double‑digit EBITDA expansion, meaningful EPS improvement), meaningful pipeline and commercial traction (complex generics, biosimilars, specialty launches like Krexone and an auto‑injector), and clear balance sheet improvement. Management also flagged near‑term headwinds and timing risks—AvKARE revenue reset, flat Affordable Medicines in Q4, generic erosion in specialty, and supply‑chain/timing for certain launches—which cap near‑term upside. On balance the company appears to be transitioning to higher‑value, higher‑margin products with deliberate investments (biosimilars, GLP‑1 manufacturing) and improved financial flexibility, while acknowledging execution and timing risks that may temper 2026 results.Company Guidance
Consolidated Revenue and Profitability Growth (2025)
Full-year 2025 revenue of $3.0B, up 8% year-over-year; full-year adjusted EBITDA of $688M, up 10%; full-year adjusted EPS $0.83, up 43%.
Strong Q4 2025 Results
Q4 2025 revenue of $814M, up 11% YoY; Q4 adjusted EBITDA $175M, up 13% YoY; Q4 adjusted EPS $0.21, up 75% YoY.
Segment Strength — Specialty
Specialty revenues grew 19% for the full year and 38% in Q4 to $167M, driven by branded products including Krexone (Crexone/Trexon) and initial sales of the new auto-injector.
Balance Sheet and Cash Flow Improvements
Operating cash flow of $340M in 2025; net leverage reduced to 3.5x (from 7.4x in 2019); weighted average cost of debt reduced from ~10% in 2024 to ~6.8% in 2026; interest expense down to $217M in 2025 from $256M in 2024; debt maturities extended to 2032.
2026 Financial Guidance (Growth with Margin Expansion)
2026 guidance: revenue $3.05B–$3.15B (up 1%–4%); adjusted EBITDA $720M–$760M (up 5%–10%); adjusted EPS $0.93–$1.03 (up 12%–20%); adjusted gross margin expected >44% (≈+100 bps).
Pipeline & Complex Launch Cadence
High launch activity: company expects to file 10–15 key complex programs in 2026; 59 ANDAs pending (64% classified as complex) and 52 more products in development (94% complex). Annual target of 20–30 new Affordable Medicines launches.
Biosimilars and GLP‑1 Strategic Progress
Biosimilars momentum: approvals for two additional biosimilars (fourth and fifth), ZOLAR in review, on track for six U.S. biosimilars by 2027; Xolair identified as a large upcoming opportunity (~$4B U.S. market). GLP‑1 collaboration with Pfizer progressing and two GLP‑1 manufacturing facilities are on target.
Commercial Traction for New Specialty Products
Krexone one-year post-launch: ~23,000 patients on therapy (~>3% market share) with interim Phase 4 showing +3.13 hours of 'good on' time for converted IR patients; management expects to double market share and more than double revenue in 2026. Launched a first‑of‑kind auto-injector for severe migraine/cluster headache (early uptake described as beyond expectations).
AMRX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
AMRX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Feb 27, 2026 | $14.49 | $13.81 | -4.69% |
Oct 30, 2025 | $10.43 | $10.00 | -4.12% |
Aug 05, 2025 | $7.96 | $8.13 | +2.14% |
May 02, 2025 | $7.74 | $7.97 | +2.97% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Amneal Pharmaceuticals Inc (AMRX) report earnings?
Amneal Pharmaceuticals Inc (AMRX) is schdueled to report earning on May 01, 2026, Before Open (Confirmed).
What is Amneal Pharmaceuticals Inc (AMRX) earnings time?
Amneal Pharmaceuticals Inc (AMRX) earnings time is at May 01, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is AMRX EPS forecast?
AMRX EPS forecast for the fiscal quarter 2026 (Q1) is 0.18.
